home / stock / ifrx / ifrx quote
Last: | $1.42 |
---|---|
Change Percent: | 6.77% |
Open: | $1.37 |
Close: | $1.33 |
High: | $1.45 |
Low: | $1.32 |
Volume: | 93,296 |
Last Trade Date Time: | 04/29/2024 03:00:00 am |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$1.42 | $1.37 | $1.33 | $1.45 | $1.32 | 93,296 | 04-29-2024 |
$1.33 | $1.41 | $1.33 | $1.429 | $1.28 | 169,301 | 04-26-2024 |
$1.39 | $1.36 | $1.39 | $1.41 | $1.26 | 146,063 | 04-25-2024 |
$1.36 | $1.37 | $1.36 | $1.45 | $1.33 | 71,453 | 04-24-2024 |
$1.36 | $1.37 | $1.36 | $1.46 | $1.32 | 97,199 | 04-23-2024 |
$1.37 | $1.35 | $1.37 | $1.41 | $1.31 | 116,449 | 04-22-2024 |
$1.35 | $1.27 | $1.35 | $1.38 | $1.27 | 136,142 | 04-19-2024 |
$1.26 | $1.26 | $1.26 | $1.42 | $1.25 | 120,599 | 04-18-2024 |
$1.265 | $1.33 | $1.265 | $1.3375 | $1.24 | 274,068 | 04-17-2024 |
$1.31 | $1.38 | $1.31 | $1.41 | $1.25 | 178,127 | 04-16-2024 |
$1.39 | $1.4995 | $1.39 | $1.5 | $1.37 | 145,903 | 04-15-2024 |
$1.5 | $1.54 | $1.5 | $1.55 | $1.45 | 223,615 | 04-12-2024 |
$1.54 | $1.6 | $1.54 | $1.65 | $1.51 | 114,727 | 04-11-2024 |
$1.52 | $1.54 | $1.52 | $1.66 | $1.51 | 933,830 | 04-10-2024 |
$1.62 | $1.53 | $1.62 | $1.66 | $1.46 | 453,659 | 04-09-2024 |
$1.52 | $1.59 | $1.52 | $1.64 | $1.51 | 80,601 | 04-08-2024 |
$1.55 | $1.56 | $1.55 | $1.68 | $1.5 | 365,160 | 04-05-2024 |
$1.56 | $1.55 | $1.56 | $1.5957 | $1.5 | 140,066 | 04-04-2024 |
$1.55 | $1.54 | $1.55 | $1.66 | $1.52 | 221,929 | 04-03-2024 |
$1.54 | $1.52 | $1.54 | $1.58 | $1.51 | 56,341 | 04-02-2024 |
News, Short Squeeze, Breakout and More Instantly...
InflaRx N.V. Company Name:
IFRX Stock Symbol:
NASDAQ Market:
JENA, Germany, April 24, 2024 (GLOBE NEWSWIRE) -- InflaRx N.V. (NASDAQ:IFRX), a biotechnology company pioneering anti-inflammatory therapeutics ...
JENA, Germany, April 24, 2024 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biotechnology company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced that the Company will participate in the Capital One Securities 1st Annual Biotech/Biopharma Disrupt...
InflaRx will focus development activities and resources initially on selected indications in immuno-dermatology, with registrational-phase vilobe...